Aperçu des produits pour anti-BRCA2 (BRCA2) Anticorps

Full name:
anti-Breast Cancer 2, Early Onset Anticorps (BRCA2)
Chez www.anticorps-enligne.fr sont 91 Breast Cancer 2, Early Onset (BRCA2) Anticorps de 22 de différents fournisseurs disponibles. De plus, nous expédions BRCA2 Kits (28) et BRCA2 Protéines (5) et beaucoup plus de produits pour cette protéine. Un total de 127 BRCA2 produits sont actuellement listés.
30169, AI256696, AW045498, BcDNA:SD25109, BRCA2, brcc2, brovca2, CG13583, CG13584, CG30169, dmbrca2, Dmel\\CG30169, facd, fad, fad1, fancb, FANCD, Fancd1, GLM3, PNCA2, RAB163
afficher tous les anticorps Gène GeneID UniProt
BRCA2 675 P51587
BRCA2 360254  
BRCA2 12190 P97929

Afficher toutes les espèces

Afficher tous les synonymes

Réactivités les plus populaires pour anti-BRCA2 (BRCA2) Anticorps

Sélectionnez vos espèces et l'application

anti-Human BRCA2 Anticorps:

anti-Rat (Rattus) BRCA2 Anticorps:

anti-Mouse (Murine) BRCA2 Anticorps:

Tous anti-BRCA2 Anticorps disponible

Vous arrivez à notre recherche pré-filtrée.

anti-BRCA2 Anticorps mieux référencés

  1. Human Monoclonal BRCA2 Primary Antibody pour IHC, IHC (p) - ABIN445491 : Wu, Jiang, Thangaraju, Wu, Couch: Induction of the BRCA2 promoter by nuclear factor-kappa B. dans The Journal of biological chemistry 2000 (PubMed)
    Show all 2 references for 445491

  2. Human Monoclonal BRCA2 Primary Antibody pour IHC, IHC (fro) - ABIN445493 : Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. dans Breast cancer research : BCR 2001 (PubMed)
    Show all 2 references for 445493

  3. Human Polyclonal BRCA2 Primary Antibody pour IHC, ELISA - ABIN1533759 : Wooster, Bignell, Lancaster, Swift, Seal, Mangion, Collins, Gregory, Gumbs, Micklem: Identification of the breast cancer susceptibility gene BRCA2. dans Nature 1996 (PubMed)
    Show all 2 references for 1533759

Plus d’anticorps contre BRCA2 partenaires d’interaction

Zebrafish Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. Carcinogenesis in zebrafish with combined mutations in tp53 (Montrer TP53 Anticorps) and brca2 typically requires biallelic mutation or loss of at least one of these genes.

  2. The novel role of Brca2 in organizing the vertebrate egg nucleus may provide new insights into the origin of ovarian cancer

  3. critical roles for brca2 in ovarian development and tumorigenesis in reproductive tissues

Mouse (Murine) Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. we generated a Brca2 knock-in mouse model lacking exons 4-7 and demonstrated that these exons are dispensable for viability as well as tumor-free survival. This study provides the first in vivo evidence of the functional significance of a minor transcript of BRCA2 that can play a major role in the survival of humans who are homozygous for a clearly pathogenic mutation.

  2. we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 (Montrer PALB2 Anticorps) by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 (Montrer PALB2 Anticorps) and Trp53 (Montrer TP53 Anticorps) heterozygosity .

  3. Merit40 (Montrer BABAM1 Anticorps) mutation exacerbated ICL-induced chromosome instability in the context of concomitant Brca2 deficiency but not in conjunction with Fancd2 (Montrer FANCD2 Anticorps) mutation.

  4. Heterozygous and homozygous Brca2 mutation may lead to dysfunction in T cell populations.

  5. BRCA2 exon 27 domain maintains chromosomal integrity at both stalled and collapsed replication forks consistent with involvement in both replication fork maintenance and double strand break repair.

  6. we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP (Montrer PARP1 Anticorps) inhibition.

  7. BRCA2-mediated sequestration of nuclear RAD51 (Montrer RAD51 Anticorps) serves to prevent inappropriate DNA interactions.

  8. BRCA2 directly represses the expression of IFN-related genes

  9. the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2

  10. genetic stability, and hematopoietic differentiation potential of gene-corrected Brca2(Delta) (27/) (Delta) (27) iPSCs, achievements and limitations in the application of current reprogramming approaches in hematopoietic stem cell therapy are also discussed.

Human Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. These results reveal a synthetic lethal relationship between FANCD2 and BRCA1/2.

  2. This study implicates novel risk loci as well as highlights the clinical utility for retesting BRCA1/2 negative ovarian cancer patients by genomic sequencing and analysis of genes in relevant pathways.

  3. Women with BRCA1/2 mutations show at diagnosis higher peritoneal tumor load and increased frequency of bulky lymph nodes compared to patients without germline BRCA mutations. Primary debulking surgery seems to ensure a longer progression-free survival in women with BRCA wild type genotype compared to neoadjuvant chemotherapy.

  4. Sixteen VUS from 51 BRCA1 variants of uncertain significance (VUS) carriers and 28 VUS from 62 BRCA2 VUS carriers were analyzed. There was a slight agreement between the two analyses, with a kappa value of 0.14 (95% confidence interval (CI) = -0.34 to 0.62) for the BRCA1 VUS and a kappa value of 0.17 (95% CI = -0.10 to 0.49) for the BRCA2 VUS

  5. Study showed that the prevalence of BRCA1/2 germline mutations was 19% in epithelial ovarian cancer, mostly detected in different gene locations. Two novel frameshift mutations were identified, one in BRCA1 and one in BRCA2, as well as two large deletions.

  6. Architectural plasticity of human BRCA2-RPA (Montrer RPA1 Anticorps)-RAD51 (Montrer RAD51 Anticorps) complexes in DNA break repair has been described.

  7. This study shows that BRCA mutation carriers could be frequently identified among breast cancer patients with multiple risk factors. Importantly, we established an NGS-based pipeline for BRCA1/2 testing in clinical practice and strongly suggest that breast cancer patients of premier- and moderate-grade risks receive BRCA1/2 mutations testing in China

  8. Studies suggest that people with high risk of breast cancer and negative BRCA1/BRCA2 should be tested for PALB2 (Montrer PALB2 Anticorps) mutations.

  9. These findings suggest that R2787H variant of BRCA2 could have potential functional impact.

  10. Even if a BRCA2 mutation is already identified within a family, the presence of early onset breast cancer affected non-carriers hampers accurate risk estimates for both mutation carriers and other negative family members.

BRCA2 profil antigène

Antigen Summary

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.

Alternative names and synonyms associated with BRCA2

  • breast cancer 2, early onset (BRCA2) anticorps
  • Breast cancer 2, early onset homolog (Brca2) anticorps
  • breast cancer 2, early onset (Brca2) anticorps
  • breast cancer 2, early onset (brca2) anticorps
  • breast cancer 2 (Brca2) anticorps
  • 30169 anticorps
  • AI256696 anticorps
  • AW045498 anticorps
  • BcDNA:SD25109 anticorps
  • BRCA2 anticorps
  • brcc2 anticorps
  • brovca2 anticorps
  • CG13583 anticorps
  • CG13584 anticorps
  • CG30169 anticorps
  • dmbrca2 anticorps
  • Dmel\\CG30169 anticorps
  • facd anticorps
  • fad anticorps
  • fad1 anticorps
  • fancb anticorps
  • FANCD anticorps
  • Fancd1 anticorps
  • GLM3 anticorps
  • PNCA2 anticorps
  • RAB163 anticorps

Protein level used designations for BRCA2

BRCA1/BRCA2-containing complex, subunit 2 , breast and ovarian cancer susceptibility gene, early onset , breast cancer 2 tumor suppressor , breast cancer type 2 susceptibility protein , fanconi anemia group D1 protein , truncated breast and ovarian cancer susceptibility protein 2 , breast cancer 2, early onset homolog , CG30169-PA , Brca2-PA , breast cancer 2, mutation 1, University of Wisconsin-Madison , breast cancer susceptibility protein 2 , breast cancer type 2 susceptibility protein homolog , fanconi anemia group D1 protein homolog , breast and ovarian cancer susceptibility protein 2 , breast cancer 2, early onset , breast cancer type 2 susceptibility protein-like

675 Homo sapiens
37916 Drosophila melanogaster
360254 Rattus norvegicus
374139 Gallus gallus
493878 Felis catus
566758 Danio rerio
584780 Strongylocentrotus purpuratus
721981 Macaca mulatta
100397509 Callithrix jacchus
452526 Pan troglodytes
474180 Canis lupus familiaris
100038818 Xenopus (Silurana) tropicalis
100601625 Nomascus leucogenys
12190 Mus musculus
100064578 Equus caballus
507069 Bos taurus
Fournisseurs de qualité sélectionnés pour anti-BRCA2 (BRCA2) Anticorps
Avez-vous cherché autre chose?